Bolivia Medical Device Risk Classification I, IIa, IIb, III: GHTF Rules and Self-Declaration

1. Key takeaways

Bolivia applies a four-level risk classification: Class I (low risk), Class IIa (low to medium risk), Class IIb (medium to high risk), and Class III (high risk). Section 1.7 of the Medical Device Sanitary Registration Manual establishes the four levels. Section 1.7.2 expressly recognizes the classification rules of the Global Harmonization Task Force (GHTF) and reproduces all 16 rules, covering non-invasive, invasive, and active devices, together with special rules for devices incorporating medicinal substances, devices utilizing animal or human tissues, devices for disinfection or cleaning, and contraceptive devices. Section 1.7.1(d) provides that where several rules apply simultaneously, the highest classification governs. The risk class is self-declared by the applicant (Section 2.4.7: if the free sale certificate does not state a class, the class designated by the manufacturer is entered), and AGEMED retains the power to reclassify on the basis of post-market experience. GRZAN considers the combination of self-declaration and subsequent reclassification to be the largest compliance exposure in the classification stage of the Bolivian system, because every downstream requirement, from samples to clinical evidence, is keyed to the class stated in the dossier.

The GHTF basis of the classification also has a practical advantage for multinationals: the 16 rules are the same rules that shaped the classification systems of many other jurisdictions, so a manufacturer that has already written a classification rationale for another GHTF-derived market can adapt it to Bolivia comparatively quickly. The adaptation still has to be done against the manual’s own text, because the wording and the numbering belong to the manual, but the underlying engineering analysis is reusable. GRZAN structures the classification rationale so that it cites the manual’s section numbers while keeping the technical reasoning portable across markets.

2. Legal basis

3. Expert insights

Insight one: self-declaration of the class is not self-certification of compliance. Section 2.4.7 permits the class designated by the manufacturer to be entered when the free sale certificate does not state a class. This offers convenience, but it also leaves AGEMED room to challenge the classification afterwards. If AGEMED reclassifies a product on the basis of post-market experience, the issued certificate and the documentation requirements that follow both change as a consequence. GRZAN recommends proactively attaching a classification rationale to the dossier, setting out clearly how each of the 16 rules was applied, rather than simply entering a class letter and leaving the reasoning implicit.

Insight two: public sources contain both a Classes I to III formulation and a Classes I to IV formulation. Some third-party sources give four levels as I / IIa / IIb / III, others give four levels as I to IV or use the A to D notation of the IMDRF. The four-level structure of Section 1.7 of the manual is self-consistent with the GHTF naming (I, IIa, IIb, III). GRZAN recommends adopting the manual’s GHTF notation uniformly in formal documents, so that correspondence with AGEMED, tender documents, and distributor agreements all speak the same classification language.

Insight three: the classification level directly determines three practical matters. First, sample requirements (only Class I devices must submit samples). Second, the strength of clinical evidence required (Section 2.4.8 sets the expectations for medium-to-high and high risk). Third, the viable path for subsequent additions (Section 5.10.2 requires the same group and the same class). Classification is not a paperwork exercise: it determines the cost of changes across the entire life cycle of a certificate that is valid for 5 years.

Insight four: the reclassification power prices itself into the planning. Because AGEMED can reclassify on the basis of post-market experience, the prudent assumption is not that the declared class is final but that it must remain defensible for the life of the certificate. That assumption changes behavior in concrete ways: vigilance records, complaint handling, and periodic reviews of the technical file all feed the defensibility of the class, and any product change that could move the product across a rule boundary triggers a fresh pass through the 16 rules. Companies that treat the class as a one-time decision usually discover the gap at renewal, when five years of history are reviewed against a rationale that was never updated.

4. Practical recommendations

The three recommendations below are ordered by cost of implementation. The classification rationale page is a drafting task; requesting the class on the free sale certificate is a coordination task with the issuing authority of the country of origin; and the distribution agreement clause is a negotiation task. Starting them in that order keeps the critical path clear, because the free sale certificate and the agreement both take longer to obtain than the rationale page takes to write.

1. Attach a classification rationale page to every dossier, explaining rule by rule which of the 16 rules apply and why the highest applicable class was taken.
2. Ask for the class to be stated on the free sale certificate where possible, reducing reliance on the self-declaration route.
3. Write the class into the distribution agreement, making clear how costs and responsibilities are shared if a reclassification by AGEMED forces an upgrade of the documentation.

5. Verification checklist

• □ Has the product been compared rule by rule against the 16 rules of Section 1.7.2 of the manual
• □ Where several rules compete, has the highest class been taken in accordance with Section 1.7.1(d)
• □ Does the free sale certificate state the risk class
• □ Is the self-declared class consistent with the statement in the technical documentation under Section 2.4.7
• □ Has the class driven the corresponding arrangements for samples, clinical evidence, and the path for additions

Regulatory information verified as of October 29, 2026.

GRZAN supports manufacturers, importers, and authorized representatives with medical device registration in Bolivia, covering dossier preparation, local entity coordination, and regulatory strategy. Contact info@grzanglobal.com for project inquiries.